Filgrastim (G-CSF) (Neupogen) , TBO-Filgrastim (Granix)


JCODE: J1440 (300 mcg); J1441 (480 mcg)

Approved for the following indications (TBO-Filgrastim preferred unless noted below):

  • Prophylaxis in pts with non-myeloid leukemia, lymphoma, solid tumor, or recurrent myeloid malignancy who are receiving myelosuppressive chemotherapeutic agents

  • Bone marrow transplantation (Neupogen preferred)

  • Treatment of patients receiving myelosuppressive anticancer drug with neutropenia

  • Following Radiotherapy

  • Dose Dense Chemotherapy for Breast Cancer

Indications that require prior authorization:

  • Congenital agranulocytosis

  • Cyclic neutropenia

  • Myelodysplastic syndromes

  • AIDS pts. on myelosuppressive therapy

  • Active infection with febrile neutropenia

  • Drug-induced neutropenia in an HIV-infected patient (Septra, ganciclovir) when therapy cannot be stopped or modified

When the above conditions (3-6) are met, approve if:

  • Initial absolute neutrophil count (ANC) <800/mm or ANC < 1000/mm with expected neutropenia of > 5 days

  • For cyclic neutropenia and congenital granulocytosis, must have at least 3 clinically significant infections requiring antibiotic therapy, or at least one life threatening infection within the past year

  • Peg-Interferon induced neutropenia, only when decreasing Peginterferon dose by 50% does not result in ANC > 750

The following do not meet criteria for coverage:

  • Auto Immune Disorders

  • Burn Patients

  • CML

  • Chronic Infections

  • ANC > 1000/mm


  • 5 mcg/kg/day; if no increase in ANC is seen after 5 days, the dose of filgrastim may be increased to 10mcg/kg/day. If ANC does not increase after additional 5 days, discontinue treatment

  • Dosing is titrated to maintain ANC between 800/mm – 1400/mm

  • Dosing continued beyond 10 days only if response is documented

  • Initial: 10 days, then re-evaluate. If response is seen, may allow up to two months, then must re-review

  • Dosage for chemotherapy: 5 mcg/Kg/day beginning day after chemotherapy and continuing past the expected nadir and discontinued when ANC > 3000

  • Neulasta (pegfilgrastim) has no therapeutic advantage over filgrastim. Neulasta requires a prior authorization for intolerance to filgrastim


Last review date: July 24, 2016

The site you are transferring to is not hosted by WHA. WHA's Terms of Use and internet Privacy Practices do not apply to your use of this linked site. Please review the policies on privacy and terms of use for the linked site. WHA does not control the accuracy, completeness, or timeliness of the content on the linked site.

Press Esc to cancel

El sitio Web al que está siendo transferido no es provisto por WHA. Las Condiciones de Uso y las Prácticas de Privacidad en Internet de WHA no se aplican a este sitio Web asociado que usted está usando. Revise las políticas sobre la privacidad y condiciones de uso de este sitio Web asociado. WHA no tiene control sobre la exactitud, la totalidad o la actualidad del contenido del sitio Web asociado. WHA no puede garantizar que los servicios de traducción de idiomas estarán disponibles en el sitio vinculado.

Presione «Esc» para cancelar